{
    "clinical_study": {
        "@rank": "80713", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "Cohort B", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity"
            }, 
            {
                "arm_group_label": "Cohort C", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity"
            }, 
            {
                "arm_group_label": "Cohort D", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-cohort, open label, Phase II study with Dabrafenib (GSK2118436) and\n      Trametinib (GSK1120212) combination therapy in subject with BRAF mutation-positive melanoma\n      that has metastasized to the brain. This study will evaluate the safety and efficacy of 4\n      cohorts. Cohorts will consist of; V600 E, D, K, R mutations, metastases to the brain,\n      symptomatic and asymptomatic, with or  without prior local (brain) therapy,  with or without\n      prior local (brain) therapy, and range of  ECOG scores from 0-2."
        }, 
        "brief_title": "Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma and Brain Metastases", 
        "condition_browse": {
            "mesh_term": [
                "Melanoma", 
                "Neoplasm Metastasis", 
                "Brain Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ECOG Performance Status range of 0-2\n\n          -  Histologically confirmed cutaneous metastatic melanoma of V600 E, K, D or R.\n\n          -  May be systemic na\u00efve or received up to two previous systemic treatment regimens for\n             metastatic melanoma.\n\n          -  Must be able to undergo MRI and have at least one measurable intracranial lesion for\n             which specific criteria have to be met.\n\n        Exclusion Criteria:\n\n          -  Prior treatment with any BRAF inhibitor or any mitogen-activated\n             protein/extracellular signal-regulated kinase inhibitor.\n\n          -  Anti-cancer therapy or investigational anti-cancer therapy or chemotherapy without\n             delayed toxicity within treatment specific timeframe.\n\n          -  Treatment with stereotactic radiosurgery or treatment with whole-brain radiation\n             within treatment specific timeframe.\n\n          -  Any presence of leptomeningeal disease or any parenchymal brain metastasis\n\n          -  History of another malignancy, some exceptions may apply.\n\n          -  A history or evidence of cardiovascular risk- specific criteria have to be met\n\n          -  A history or current evidence/risk of retinal vein occlusion or retinal pigment\n             epithelial detachment - specific criteria have to be met."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039947", 
            "org_study_id": "117277"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort B", 
                    "Cohort C", 
                    "Cohort A", 
                    "Cohort D"
                ], 
                "description": "Dabrafenib will be provided as 50 mg and 75 mg capsules", 
                "intervention_name": "Dabrafenib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort B", 
                    "Cohort C", 
                    "Cohort A", 
                    "Cohort D"
                ], 
                "description": "Trametinib will be provided as 0.5 mg and 2.0 mg tablets", 
                "intervention_name": "Trametinib", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "BRAF V600K mutation", 
            "Metastatic Melanoma", 
            "BRAF V600R mutation", 
            "BRAF V600D mutation", 
            "BRAF V600E mutation", 
            "Brain metastases BRAF inhibitor", 
            "Intracranial"
        ], 
        "lastchanged_date": "January 16, 2014", 
        "number_of_arms": "4", 
        "official_title": "BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Intracranial response (IR) rate", 
            "safety_issue": "No", 
            "time_frame": "Approximately 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039947"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Intracranial response rate of cohorts B, C and D", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Disease Control for intracranial, extracranial and overall response for each cohort", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Extracranial response rate (ER) for each cohort", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Overall response (OR) for each cohort", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Duration of intracranial, extracranial and overall response for each cohort", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Progression-free survival (PFS) for each cohort", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Overall survival (OS) for each cohort", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "description": "12-lead electrocardiograms (ECG), echocardiograms, and clinical monitoring/observation including neurological examination", 
                "measure": "Characterize the safety of dabrafenib and trametinib in combination therapy for all cohorts. Safety will be measured by the frequency and severity of adverse events, skin assessments, laboratory abnormalities, vital signs, and assessment data.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}